eyenovia-logo 3

News Releases

News Releases

05/12/22

Mydcombi™ NDA resubmission on track for Q3 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressing as planned; topline data expected mid-year Ended Q1 with sufficient cash and cash equivalents for the potential launch of Mydcombi
05/05/22

Company to host an investor conference call and webcast at 4:30pm ET on that day NEW YORK , May 05, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company
04/20/22

Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology NEW YORK , April 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose
04/19/22

Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array print (MAP™) spray using the company’s proprietary OpteJet® dispenser NEW YORK , April 19, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company
03/28/22

Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022 Enrolled first patient in the Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) Entered into a $15 million Securities Purchase Agreement
03/21/22

Company to host an investor conference call and webcast at 4:30pm ET on that day NEW YORK , March 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the
03/15/22

Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications NEW YORK , March 15, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology
03/04/22

NEW YORK , March 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a Securities Purchase Agreement with Armistice Capital
02/08/22

No additional clinical work required; NDA resubmission anticipated in Q3 2022 NEW YORK , Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the
02/07/22

NEW YORK , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced changes to its Board of Directors. Dr. Sean Ianchulev , Director, Chief Executive Officer